We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Edwards Lifesciences Corp | NYSE:EW | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 85.25 | 0 | 10:50:17 |
From May 2019 to May 2024
By Colin Kellaher
Edwards Lifesciences Corp. Wednesday said the U.S. Food and Drug Administration approved its Konect Resilia aortic valved conduit for complex aortic-valve surgeries.
The Irvine, Calif., company said the product is the first ready-to-implant solution for bio-Bentall procedures, which involve replacement of a patient's aortic valve, aortic root and the ascending aorta.
Edwards said the device can streamline treatment for patients requiring the complex and technical surgery, noting that up to 30% of Bentall procedures are performed in an emergency setting.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 15, 2020 09:02 ET (13:02 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Edwards Lifesciences Chart |
1 Month Edwards Lifesciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
